The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics

Table of Contents

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

• 4.1 List of Boxes
• 4.2 List of Figures
• 4.3 List of Tables

5 Cancer Antibodies: The Growth Engine of the Pharmaceutical Market

• 5.1 Where We Stand Today
• 5.2 The Current Antibody Cancer Pipeline of Big Pharma and Biotech
• 5.3 Recent Changes in the Competitive Landscape of Monoclonal Antibody Technologies
  • 5.3.1 Big Pharma' s Race for Monoclonal Technologies
  • 5.3.2 The Race to the First Approved Miniature Antibody
• 5.4 Technology Platform Approaches to Monoclonal Antibody Therapeutics
• 5.5 Drug Discovery and Development Platforms

6 Monoclonal Antibody Technologies- Protein Engineering and Library Platforms

• 6.1 From Mouse to Human Mabs
• 6.2 Human Antibodies from Transgenic Mice
• 6.3 Library Display Platforms
• 6.4 Antibodies Blown to Bits: From Full Length to Fragments

7 Classification of Technology Platforms by Monoclonal Antibody Specifics

• 7.1 Monoclonal Antibody Sources
  • 7.1.1 B cells
  • 7.1.2 Plasma
  • 7.1.3 Cancer Stem Cells and Tumor Tissue

8 Active Immunotherapeutic Platforms Using Monoclonal Antibodies

• 8.1 Antigen Presenting Cells/Dendritic Cells
• 8.2 T cells

9 Monoclonal Immuoconjugates: Strategies and Platforms

• 9.1 Cytotoxin-Conjugated Antibody Platforms
• 9.2 Radioisotope-Conjugated Antibody Platforms
• 9.3 Antibody-Linker Platforms
• 9.4 Vasculature-Targeting Platforms

10 Monoclonal Antibody Expression Platforms

• 10.1 Mammalian Cell, Bacterial and Hybridoma Platform Technologies
• 10.2 Plant and Animal Platforms of Antibody Production
• 10.3 Monoclonal Antibody Processing Platforms

11 Monoclonal Antibody Platforms for Non-Protein Targets

• 11.1 Monoclonal Antibody Platforms for Carbohydrate
• 11.2 Monoclonal Antibody Platforms for Lipid

12 Post-Translational Modification Platforms

• 12.1 Glycosylation modification

13 Novel Strategies for Monoclonal Antibody Delivery

• 13.1 Gene Delivery and Transfer Technologies
• 13.2 Epidermal Delivery

14 Monoclonals Based on Non-IgG1 Immunoglobulin Structures

15 Alternative Non-Antibody Protein Binding Technologies

16 Monoclonal Antibody Technology Profiles _____(Truncated list)

• 16.1 AbGenomics
  • 16.1.1 AbProt™
  • 16.98.1 Human Engineering™ Technology HE™ technology
  • 16.98.2 Microbial Expression Technology

18 Technology Platform Index

19 Company Index

4.1 List of Boxes

• Box 1: Desirable Immunogenicity from a Murine Antibody
• Box 2: mAb Competition for CD200
• Box 3: Using mAb Fragments to Bind Intracellular Targets
• Box 4: Cancer Stem Cells: A New Paradigm in Cancer Therapeutics
• Box 5: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies

4.2 List of Figures

• Figure 1: Developmental Status of the Antibody-based Pharmaceutical Pipeline in Oncology
• Figure 2: Top 10 Big Pharma Cancer mAb Pipeline
• Figure 3: Top 10 Biotech Company Cancer mAb Pipeline
• Figure 4: Investigator Country of Origin
• Figure 5: Company Breakdown by Platform Classification

4.3 List of Tables

• Table 1: Monoclonal Antibody Therapeutics Approved for Cancer Indications
• Table 2: Recent Noteworthy Acquisitions and Mergers in the mAb-based Oncology Therapeutic Market
• Table 3: TechPlatforms of Investigators Involved in Monoclonal Antibody Therapy of Cancer
• Table 4: Selected Companies and their Antibody Species Specificity
• Table 5: Pipeline of the Four Investigators with Transgenic Mouse Technology
• Table 6: Library Display Platform Technologies
• Table 7: Full Size Antibodies vs Antibody Fragments
• Table 8: Research Platforms for Cancer Immunotherapy using Antibody Fragments/Formats
• Table 9: Developmental Stage of Selected Bispecific Antibodies
• Table 10: Developmental Stage of Selected Trispecific Antibodies
• Table 11: Human Source Material for Monoclonal Antibody Platforms
• Table 12: Monoclonal Antibody Technology Platforms for Immune Cell Activation
• Table 13: Monoclonal Antibody Immunoconjugates Aprroved for Cancer Indications
• Table 14: Monoclonal Antibody Immunoconjugation Technologies
• Table 15: Radioisotope Platforms for mAb Technology
• Table 16: Technology Platforms Categorized by mAb-based Expression System
• Table 17: Non-Protein Targets of Monoclonal Antibody Platforms
• Table 18: Technology Platforms for Post-Translational Modification of Monoclonal Antibodies
• Table 19: Technology Platforms Specific for mAb Delivery
• Table 20: Company Platforms Based on Non-IgG1 Immunoglobulin Structures
• Table 21: Selected Companies with Cancer-Targeting Protein Therapeutics Based on Non-IgG Domains